GENOSCIENCE PHARMA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
Phase 1
- Conditions
- Primary Liver Cancer
- Interventions
- Drug: GNS561 oral tablets and capsules
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT05353894
- Locations
- 🇫🇷
Genoscience Pharma, Marseille, France
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 178
- Registration Number
- NCT04637828
- Locations
- 🇫🇷
Genoscience Pharma, Marseille, France
Study of GNS561 in Patients With Liver Cancer
Phase 1
Terminated
- Conditions
- Hepatocellular CarcinomaCholangiocarcinoma, Intrahepatic
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Genoscience Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT03316222
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇧🇪Jules Bordet Institute, Brussel, Belgium
🇫🇷CHU Grenoble, Grenoble, France
News
GENFIT Reports Strong 2024 Financial Results with First Commercial Revenues from Iqirvo®
GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.